Updating beers criteria
Costs and adverse events associated with the use of PIMs are substantial.
According to the 2000/2001 Medical Expenditures Panel Survey, the total estimated health cost related to use of PIMs was .2 billion.
Methods: A literature review was performed targeting publications between 20 on the topics of the Beers Criteria, PIMs, and specific urologic medications included in the current version of the Beers Criteria.
An expert panel was convened to evaluate this information and create this white paper with the purpose of educating the urologic community on these issues.
Results: The rationale for creation and implementation of the Beers Criteria and its implications for urologic practice are reviewed.
It also incorporates and acknowledges specific exceptions for use of PIMs, for example in cases of palliative or end-of-life care.Conclusions: The Beers Criteria were developed to improve prescribing practices for older adult patients in order to reduce or avoid potential risks and complications.We encourage clinicians to educate themselves about the Beers Criteria recommendations and associated initiatives that are aimed at improving the care of our older adult patients. Several medications included in sections of the Beers Criteria are frequently used in clinical urology, including nitrofurantoin, the alpha1 blocker medications, and the antimuscarinic anticholinergic medications for the treatment of urge incontinence and overactive bladder. In 2012, the American Geriatrics Society (AGS) published the most recent update of the Beers Criteria for Potentially Inappropriate Medication (PIM) Use in Older Adults.